News | January 30, 2026
Biocon Biologics gets credit boost from S&P, outlook stable
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The collaboration will center on expanding access to Eastman’s Esmeri technology
The new functionality complements Parse’s existing Evercode immune products
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
Subscribe To Our Newsletter & Stay Updated
